Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence

Autores
Mazzolini Rizzo, Guillermo Daniel; Sowa, Jan Peter; Atorrasagasti, María Catalina; Kücükoglu, Özlem; Syn, Wing Kin; Canbay, Ali
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Non-alcoholic fatty liver disease (NAFLD) is defined clinicopathologically by the accumulation of lipids in >5% of hepatocytes and the exclusion of secondary causes of fat accumulation. NAFLD encompasses a wide spectrum of liver damage, extending from simple steatosis or non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH)-the latter is characterized by inflammation and hepatocyte ballooning degeneration, in addition to the steatosis, with or without fibrosis. NAFLD is now the most common cause of chronic liver disease in Western countries and affects around one quarter of the general population. It is a multisystem disorder, which is associated with an increased risk of type 2 diabetes mellitus as well as liver- and cardiovascular-related mortality. Although earlier studies had suggested that NAFL is benign (i.e., non-progressive), cumulative evidence challenges this dogma, and recent data suggest that nearly 25% of those with NAFL may develop fibrosis. Importantly, NAFLD patients are more susceptible to the toxic effects of alcohol, drugs, and other insults to the liver. This is likely due to the functional impairment of steatotic hepatocytes, which is virtually undetectable by current clinical tests. This review provides an overview of the current evidence on the clinical significance of NAFL and discusses the molecular basis for NAFL development and progression.
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Sowa, Jan Peter. Ruhr Universität Bochum; Alemania
Fil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Kücükoglu, Özlem. Otto-von-Guericke-Universität Magdeburg; Alemania
Fil: Syn, Wing Kin. Universidad del País Vasco; España. Medical University of South Carolina; Estados Unidos. University of the Basque Country; España
Fil: Canbay, Ali. Ruhr Universität Bochum; Alemania
Materia
BENIGN CONDITION
CARDIOVASCULAR RISK
DISEASE PROGRESSION
NON-ALCOHOLIC FATTY LIVER DISEASE
NON-ALCOHOLIC STEATOHEPATITIS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/181947
Acceder
id CONICETDig_fc7c78d9565ed4827df1f69f48e2ca2b
oai_identifier_str oai:ri.conicet.gov.ar:11336/181947
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Significance of Simple Steatosis: An Update on the Clinical and Molecular EvidenceMazzolini Rizzo, Guillermo DanielSowa, Jan PeterAtorrasagasti, María CatalinaKücükoglu, ÖzlemSyn, Wing KinCanbay, AliBENIGN CONDITIONCARDIOVASCULAR RISKDISEASE PROGRESSIONNON-ALCOHOLIC FATTY LIVER DISEASENON-ALCOHOLIC STEATOHEPATITIShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Non-alcoholic fatty liver disease (NAFLD) is defined clinicopathologically by the accumulation of lipids in >5% of hepatocytes and the exclusion of secondary causes of fat accumulation. NAFLD encompasses a wide spectrum of liver damage, extending from simple steatosis or non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH)-the latter is characterized by inflammation and hepatocyte ballooning degeneration, in addition to the steatosis, with or without fibrosis. NAFLD is now the most common cause of chronic liver disease in Western countries and affects around one quarter of the general population. It is a multisystem disorder, which is associated with an increased risk of type 2 diabetes mellitus as well as liver- and cardiovascular-related mortality. Although earlier studies had suggested that NAFL is benign (i.e., non-progressive), cumulative evidence challenges this dogma, and recent data suggest that nearly 25% of those with NAFL may develop fibrosis. Importantly, NAFLD patients are more susceptible to the toxic effects of alcohol, drugs, and other insults to the liver. This is likely due to the functional impairment of steatotic hepatocytes, which is virtually undetectable by current clinical tests. This review provides an overview of the current evidence on the clinical significance of NAFL and discusses the molecular basis for NAFL development and progression.Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Sowa, Jan Peter. Ruhr Universität Bochum; AlemaniaFil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Kücükoglu, Özlem. Otto-von-Guericke-Universität Magdeburg; AlemaniaFil: Syn, Wing Kin. Universidad del País Vasco; España. Medical University of South Carolina; Estados Unidos. University of the Basque Country; EspañaFil: Canbay, Ali. Ruhr Universität Bochum; AlemaniaNLM (Medline)2020-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/181947Mazzolini Rizzo, Guillermo Daniel; Sowa, Jan Peter; Atorrasagasti, María Catalina; Kücükoglu, Özlem; Syn, Wing Kin; et al.; Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence; NLM (Medline); Cells; 9; 11; 11-2020; 1-192073-4409CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/cells9112458info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2073-4409/9/11/2458info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:56Zoai:ri.conicet.gov.ar:11336/181947instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:57.143CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
title Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
spellingShingle Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
Mazzolini Rizzo, Guillermo Daniel
BENIGN CONDITION
CARDIOVASCULAR RISK
DISEASE PROGRESSION
NON-ALCOHOLIC FATTY LIVER DISEASE
NON-ALCOHOLIC STEATOHEPATITIS
title_short Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
title_full Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
title_fullStr Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
title_full_unstemmed Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
title_sort Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
dc.creator.none.fl_str_mv Mazzolini Rizzo, Guillermo Daniel
Sowa, Jan Peter
Atorrasagasti, María Catalina
Kücükoglu, Özlem
Syn, Wing Kin
Canbay, Ali
author Mazzolini Rizzo, Guillermo Daniel
author_facet Mazzolini Rizzo, Guillermo Daniel
Sowa, Jan Peter
Atorrasagasti, María Catalina
Kücükoglu, Özlem
Syn, Wing Kin
Canbay, Ali
author_role author
author2 Sowa, Jan Peter
Atorrasagasti, María Catalina
Kücükoglu, Özlem
Syn, Wing Kin
Canbay, Ali
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv BENIGN CONDITION
CARDIOVASCULAR RISK
DISEASE PROGRESSION
NON-ALCOHOLIC FATTY LIVER DISEASE
NON-ALCOHOLIC STEATOHEPATITIS
topic BENIGN CONDITION
CARDIOVASCULAR RISK
DISEASE PROGRESSION
NON-ALCOHOLIC FATTY LIVER DISEASE
NON-ALCOHOLIC STEATOHEPATITIS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Non-alcoholic fatty liver disease (NAFLD) is defined clinicopathologically by the accumulation of lipids in >5% of hepatocytes and the exclusion of secondary causes of fat accumulation. NAFLD encompasses a wide spectrum of liver damage, extending from simple steatosis or non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH)-the latter is characterized by inflammation and hepatocyte ballooning degeneration, in addition to the steatosis, with or without fibrosis. NAFLD is now the most common cause of chronic liver disease in Western countries and affects around one quarter of the general population. It is a multisystem disorder, which is associated with an increased risk of type 2 diabetes mellitus as well as liver- and cardiovascular-related mortality. Although earlier studies had suggested that NAFL is benign (i.e., non-progressive), cumulative evidence challenges this dogma, and recent data suggest that nearly 25% of those with NAFL may develop fibrosis. Importantly, NAFLD patients are more susceptible to the toxic effects of alcohol, drugs, and other insults to the liver. This is likely due to the functional impairment of steatotic hepatocytes, which is virtually undetectable by current clinical tests. This review provides an overview of the current evidence on the clinical significance of NAFL and discusses the molecular basis for NAFL development and progression.
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Sowa, Jan Peter. Ruhr Universität Bochum; Alemania
Fil: Atorrasagasti, María Catalina. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Kücükoglu, Özlem. Otto-von-Guericke-Universität Magdeburg; Alemania
Fil: Syn, Wing Kin. Universidad del País Vasco; España. Medical University of South Carolina; Estados Unidos. University of the Basque Country; España
Fil: Canbay, Ali. Ruhr Universität Bochum; Alemania
description Non-alcoholic fatty liver disease (NAFLD) is defined clinicopathologically by the accumulation of lipids in >5% of hepatocytes and the exclusion of secondary causes of fat accumulation. NAFLD encompasses a wide spectrum of liver damage, extending from simple steatosis or non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH)-the latter is characterized by inflammation and hepatocyte ballooning degeneration, in addition to the steatosis, with or without fibrosis. NAFLD is now the most common cause of chronic liver disease in Western countries and affects around one quarter of the general population. It is a multisystem disorder, which is associated with an increased risk of type 2 diabetes mellitus as well as liver- and cardiovascular-related mortality. Although earlier studies had suggested that NAFL is benign (i.e., non-progressive), cumulative evidence challenges this dogma, and recent data suggest that nearly 25% of those with NAFL may develop fibrosis. Importantly, NAFLD patients are more susceptible to the toxic effects of alcohol, drugs, and other insults to the liver. This is likely due to the functional impairment of steatotic hepatocytes, which is virtually undetectable by current clinical tests. This review provides an overview of the current evidence on the clinical significance of NAFL and discusses the molecular basis for NAFL development and progression.
publishDate 2020
dc.date.none.fl_str_mv 2020-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/181947
Mazzolini Rizzo, Guillermo Daniel; Sowa, Jan Peter; Atorrasagasti, María Catalina; Kücükoglu, Özlem; Syn, Wing Kin; et al.; Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence; NLM (Medline); Cells; 9; 11; 11-2020; 1-19
2073-4409
CONICET Digital
CONICET
url http://hdl.handle.net/11336/181947
identifier_str_mv Mazzolini Rizzo, Guillermo Daniel; Sowa, Jan Peter; Atorrasagasti, María Catalina; Kücükoglu, Özlem; Syn, Wing Kin; et al.; Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence; NLM (Medline); Cells; 9; 11; 11-2020; 1-19
2073-4409
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3390/cells9112458
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2073-4409/9/11/2458
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv NLM (Medline)
publisher.none.fl_str_mv NLM (Medline)
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613084352610304
score 13.070432

Publicaciones similares